CoChat

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Open access
Fields, Paul A., Kowalczyk, Dariusz W., Arruda, Valder R., Armstrong, Elina, McCleland, Mark L., Hagstrom, J.Nathan, Pasi, K.John, Ertl, Hildegund C.J., Herzog, Roland W., High, Katherine A. · 2000 · Molecular Therapy
Cited by 129

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Defining immune responses against the secreted transgene product in a gene therapy setting is critical for treatment of genetic diseases such as hemophilia B (coagulation factor IX deficiency). We have previously shown that intramuscular administration of an adeno-associated viral (AAV) vector results in stable expression of therapeutic levels of factor IX (F.IX) and may be associated with humoral immune responses against F.IX. This study demonstrates that intramuscular injection of an AAV vector expressing F.IX fails to activate F.IX-specific cytotoxic T lymphocytes (CTLs) in hemostatically normal or in hemophilia B mice, so that there is an absence of cellular immune responses against F.IX. However, transgene-derived F.IX can cause B cell responses characterized by production of T helper cell-dependent antibodies (predominantly IgG1, but also IgG2 subclasses) resulting from activation of CD4+ T helper cells primarily of the Th2 subset. In contrast, administration of an adenoviral vector efficiently activated F.IX-specific CTLs and T helper cells of both Th1 and Th2 subsets, leading to inflammation and destruction of transduced muscle tissue and activation of B cells as well. Therefore, vector sequences fundamentally influence T cell responses against transgene-encoded F.IX. In conclusion, activation of the immune system in AAV-mediated gene transfer is restricted to pathways mediated by F.IX antigen presentation through MHC class II determinants resulting in T and B cell responses that are more comparable to responses in the setting of protein infusion rather than of viral infection/gene transfer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1006/mthe.2000.0032

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 129

Metadata

Authors
Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, K. J., Ertl, H. C. J., Herzog, R. W., & High, K. A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2000-03
Volume
1
Issue
3
Pages
225-235
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2011891951
Cited by
129
References
2
FWCI
8.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX. https://app.cochat.ai/papers/10.1006/mthe.2000.0032
The paper
Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, K. J., Ertl, H. C. J., Herzog, R. W., & High, K. A. (2000). Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX. Molecular Therapy. https://doi.org/10.1006/mthe.2000.0032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.